IngentaConnect Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclop...

Authors: Gradishar, W. J.¹; Wedam, S. B.²; Erban, J.³; Limentani, S. A.⁴; Tsai, K.-T.⁵; Olsen, S. R.⁵; Swain, S. M.²

Source: Annals of Oncology, Volume 16, Number 8, August 2005 , pp. 1297-1304(8)

Publisher: Oxford University Press

Abstract:

Background: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer.

Patients and methods: Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m² every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated.

Results: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n=4) of patients had a pathologic complete response (pCR) in the breast, 27% (n=11) had a pCR within the axillary lymph nodes, and 7% (n=3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n=2) had minimal residual invasive tumor (<5 mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%).

Conclusions: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.

Keywords: neoadjuvant docetaxel; stage II breast cancer

Document Type: Research article

DOI: 10.1093/annonc/mdi254

Affiliations: 1: Northwestern University Feinberg School of Medicine, Chicago, IL; 2: Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, DHHS Bethesda, MD; 3: Tufts New England Medical Center, Boston, MA; 4: Carolinas-Hematology Oncology Associates and the Blumenthal Cancer Center, Charlotte, NC; 5: Aventis Pharmaceuticals, Bridgewater, NJ, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$40.19 plus tax Refund Policy

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer